These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 23737390

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ, Park DW, Kim WJ, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.
    Catheter Cardiovasc Interv; 2013 Jun 01; 81(7):1106-14. PubMed ID: 22899589
    [Abstract] [Full Text] [Related]

  • 5. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B, Yang Y, Yuan Z, Du Z, Wong SC, Généreux P, Lu S, RESOLUTE China RCT Investigators.
    JACC Cardiovasc Interv; 2013 Jul 01; 6(7):664-70. PubMed ID: 23523240
    [Abstract] [Full Text] [Related]

  • 6. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L.
    JACC Cardiovasc Interv; 2013 May 01; 6(5):504-12. PubMed ID: 23602459
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 8. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE, ENDEAVOR IV Investigators.
    JACC Cardiovasc Interv; 2010 Oct 01; 3(10):1043-50. PubMed ID: 20965463
    [Abstract] [Full Text] [Related]

  • 9. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.
    JACC Cardiovasc Interv; 2013 Dec 01; 6(12):1263-6. PubMed ID: 24239202
    [Abstract] [Full Text] [Related]

  • 10. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P, RESOLUTE All Comers, RESOLUTE International Investigators.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):905-13. PubMed ID: 23954063
    [Abstract] [Full Text] [Related]

  • 11. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 01; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 12. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB.
    JACC Cardiovasc Interv; 2009 Oct 01; 2(10):967-76. PubMed ID: 19850257
    [Abstract] [Full Text] [Related]

  • 13. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP, Burzotta F, Trani C, Tommasino A, Niccoli G, Porto I, Leone AM, Mongiardo R, Schiavoni G, Crea F.
    Catheter Cardiovasc Interv; 2013 Feb 01; 81(2):268-73. PubMed ID: 22639426
    [Abstract] [Full Text] [Related]

  • 14. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT, Sun H, Zhang DP, Xu L, Ni ZH, Xia K, Liu Y, Chi YH, He JF, Li WM, Wang HS, Wang LF, Yang XC.
    Coron Artery Dis; 2014 Aug 01; 25(5):405-11. PubMed ID: 24584031
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A, Sardi G, Hauville C, Barbash IM, Pakala R, Torguson R, Xue Z, Satler LF, Pichard AD, Waksman R.
    Catheter Cardiovasc Interv; 2013 Apr 01; 81(5):759-65. PubMed ID: 22488756
    [Abstract] [Full Text] [Related]

  • 16. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB.
    JACC Cardiovasc Interv; 2011 May 01; 4(5):543-50. PubMed ID: 21596327
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S, Serruys PW, Leon MB, Meredith IT, Windecker S, Neumann FJ, Belardi J, Widimsky P, Massaro J, Novack V, Yeung AC, Saito S, Mauri L.
    JACC Cardiovasc Interv; 2013 Apr 01; 6(4):357-68. PubMed ID: 23523454
    [Abstract] [Full Text] [Related]

  • 18. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
    Hannan EL, Zhong Y, Wu C, Walford G, Holmes DR, Jacobs AK, Stamato NJ, Venditti FJ, Sharma S, Fergus I, King SB.
    Catheter Cardiovasc Interv; 2013 Jun 01; 81(7):1097-105. PubMed ID: 22707353
    [Abstract] [Full Text] [Related]

  • 19. Comparison of 2-year clinical outcomes between zotarolimus-, sirolimus-, and paclitaxel-eluting stents in real life clinical practice.
    Kim JH, Park KW, Lim WH, Shin DH, Chae IH, Choi DJ, Kim HS.
    Catheter Cardiovasc Interv; 2014 Feb 15; 83(3):349-59. PubMed ID: 24654284
    [Abstract] [Full Text] [Related]

  • 20. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y, Colleran R, Kufner S, Giacoppo D, Rheude T, Michel J, Cassese S, Ibrahim T, Laugwitz KL, Kastrati A, Byrne RA, Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus- Eluting Stents (ISAR-TEST 5) Investigators.
    Cardiovasc Diabetol; 2016 Sep 01; 15(1):124. PubMed ID: 27586678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.